BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,039 filers reported holding BAXTER INTL INC in Q1 2015. The put-call ratio across all filers is 0.65 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,999,014 | -15.0% | 119,552 | +8.6% | 0.22% | -17.2% |
| Q1 2024 | $4,705,076 | +122.1% | 110,086 | +100.9% | 0.27% | +111.0% |
| Q4 2023 | $2,118,134 | -25.8% | 54,789 | -27.6% | 0.13% | -28.2% |
| Q3 2023 | $2,856,117 | +82950.8% | 75,679 | +0.3% | 0.18% | -6.8% |
| Q2 2023 | $3,439 | -100.0% | 75,478 | -85.7% | 0.19% | -94.0% |
| Q2 2015 | $37,006,000 | -0.5% | 529,184 | -2.6% | 3.15% | +1.0% |
| Q1 2015 | $37,205,000 | -9.5% | 543,138 | -3.2% | 3.12% | -7.4% |
| Q4 2014 | $41,130,000 | +8.4% | 561,195 | +6.1% | 3.37% | +10.7% |
| Q3 2014 | $37,953,000 | +3.9% | 528,818 | +4.7% | 3.04% | +3.4% |
| Q2 2014 | $36,518,000 | +0.4% | 505,088 | +2.2% | 2.94% | -6.9% |
| Q1 2014 | $36,370,000 | +8.9% | 494,290 | +2.9% | 3.16% | +6.3% |
| Q4 2013 | $33,405,000 | – | 480,304 | – | 2.98% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
| NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
| Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
| Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
| GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
| Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
| Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
| Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
| Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |